#USA #Elk Grove Village #Orsini #Cytokinetics #MYQORZO

Orsini Partners with Cytokinetics for Revolutionary Heart Disease Therapy

In a significant development for patients suffering from obstructive hypertrophic cardiomyopathy (oHCM), Orsini has officially become the specialty pharmacy partner for Cytokinetics’s MYQORZO™ (aficamten). MYQORZO™, an FDA-approved cardiac myosin inhibitor, targets symptomatic adults with oHCM, aiming to enhance their functional capacity and alleviate their symptoms. This collaboration signifies an important step in providing patients with easier access to essential therapies.

Understanding oHCM and the Role of MYQORZO™

Obstructive hypertrophic cardiomyopathy is a genetic condition that leads to abnormal thickening of the heart muscle, obstructing blood flow from the left ventricle to the aorta. This condition poses severe challenges, as it can result in shortness of breath, chest pain, fatigue, and in extreme cases, heart failure, stroke, or sudden cardiac arrest. With MYQORZO™, Cytokinetics offers hope; clinical studies have demonstrated that it significantly improves peak oxygen uptake in patients over a 24-week period, providing meaningful enhancements in their overall quality of life.

Orsini’s Commitment to Patient Care

Darin DeCarlo, the Chief Commercial Officer at Orsini, expressed his excitement about this new partnership, stating, “Orsini is honored to be entrusted to help patients access this important new therapy.” This sentiment reflects Orsini's longevity and commitment to rare diseases since its inception in 1987. With a dedicated Cardiology Center of Excellence, Orsini is well-equipped to support the oHCM community with comprehensive care strategies.

The partnership enhances Orsini's already robust portfolio, which now includes five cardiomyopathy therapies. The company prides itself on a high-touch care model, which emphasizes personalized services tailored to patients' unique needs. This ensures that when patients embark on their journey with MYQORZO™, they are provided with world-class support ranging from pharmacy distribution to clinical management and home infusion services.

Enhancing Access to Care

Orsini's approach to patient care is founded on the principle that “No Patient is Left Behind™.” This commitment is evident in their partnerships with biopharma innovators, healthcare providers, and payors to facilitate access to groundbreaking treatments for rare diseases. By simplifying the connection between patients and advanced therapies, Orsini is at the forefront of enhancing the healthcare experience for individuals grappling with rare conditions.

Moreover, Orsini has received numerous accreditations, including those from the Accreditation Commission for Health Care (ACHC) and The Joint Commission. They have also gained recognition for their Rare Disease Pharmacy Center of Excellence Designation, underscoring their capability in delivering high-quality pharmaceutical care.

Looking to the Future

As Orsini steps into this new role as a specialty pharmacy partner for MYQORZO™, the hope is that many patients suffering from oHCM will benefit from this innovative therapy. The commitment to compassionate patient care remains paramount, and through this partnership, Orsini and Cytokinetics aim to elevate the quality of life for those affected by this serious heart condition.

For further details about Orsini's services and the ongoing commitment to treating rare diseases, visit www.orsini.com.